IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+12.89%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$317M
AUM Growth
+$317M
(-3.5%)
Cap. Flow
-$31.6M
Cap. Flow
% of AUM
-9.97%
Top 10 Holdings %
Top 10 Hldgs %
36.88%
Holding
89
New
29
Increased
20
Reduced
19
Closed
19
Top Buys
| 1 |
Revvity
RVTY
|
$10M |
| 2 |
Abbott
ABT
|
$6.53M |
| 3 |
Sanofi
SNY
|
$6.27M |
| 4 |
Centene
CNC
|
$5.54M |
| 5 |
eHealth
EHTH
|
$5.53M |
Top Sells
| 1 |
Quest Diagnostics
DGX
|
$13.7M |
| 2 |
LHCG
LHC Group LLC
LHCG
|
$10.6M |
| 3 |
Bristol-Myers Squibb
BMY
|
$9.05M |
| 4 |
Danaher
DHR
|
$7.96M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$7.65M |
Sector Composition
| 1 | Healthcare | 88.17% |
| 2 | Energy | 5.03% |
| 3 | Financials | 1.75% |
| 4 | Consumer Discretionary | 0.61% |
| 5 | Technology | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Agios Pharmaceuticals
AGIO
$2.19B
| $4.2M | 1.28% | 120,000 -30,000 | -20% | -$1.05M |
|
|
ONC
27
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $4.15M | 1.27% | 14,500 +4,500 | +45% | +$1.29M |
|
28
Halozyme
HALO
$8.56B
| $4.07M | 1.25% | 155,000 +20,000 | +15% | +$526K |
|
|
RETA
29
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.9M | 1.19% | +40,000 | New | +$3.9M |
|
30
Hologic
HOLX
$14.9B
| $3.66M | 1.12% | +55,000 | New | +$3.66M |
|
31
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.64M | 1.11% | +25,000 | New | +$3.64M |
|
32
Fate Therapeutics
FATE
$120M
| $3.4M | 1.04% | 85,000 +15,000 | +21% | +$599K |
|
33
Guardant Health
GH
$8.41B
| $3.35M | 1.03% | +30,000 | New | +$3.35M |
|
34
Globus Medical
GMED
$8.27B
| $3.22M | 0.98% | +65,000 | New | +$3.22M |
|
35
Baxter International
BAX
$12.7B
| $3.22M | 0.98% | 40,000 -10,000 | -20% | -$804K |
|
36
Universal Health Services
UHS
$11.6B
| $3.21M | 0.98% | 30,000 -35,000 | -54% | -$3.75M |
|
|
37
Bristol-Myers Squibb
BMY
$96B
| $3.02M | 0.92% | 50,000 -150,000 | -75% | -$9.05M |
|
|
CTLT
38
DELISTED
CATALENT, INC.
CTLT
| $3M | 0.92% | 35,000 -65,000 | -65% | -$5.57M |
|
39
Pennant Group
PNTG
$830M
| $2.89M | 0.88% | +75,000 | New | +$2.89M |
|
40
iRhythm Technologies
IRTC
$5.46B
| $2.86M | 0.87% | +12,000 | New | +$2.86M |
|
41
Molina Healthcare
MOH
$9.8B
| $2.75M | 0.84% | 15,000 -25,000 | -63% | -$4.58M |
|
42
Bausch Health
BHC
$2.74B
| $2.72M | 0.83% | +175,000 | New | +$2.72M |
|
43
Apellis Pharmaceuticals
APLS
$3.48B
| $2.72M | 0.83% | +90,000 | New | +$2.72M |
|
44
Akero Therapeutics
AKRO
$3.74B
| $2.62M | 0.8% | +85,000 | New | +$2.62M |
|
|
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.57M | 0.78% | +100,000 | New | +$2.57M |
|
46
Karyopharm Therapeutics
KPTI
$61.7M
| $2.56M | 0.78% | 175,000 +100,000 | +133% | +$1.46M |
|
47
Gossamer Bio
GOSS
$562M
| $2.48M | 0.76% | 200,000 -70,000 | -26% | -$869K |
|
48
DexCom
DXCM
$29.5B
| $2.47M | 0.76% | 6,000 -9,000 | -60% | -$3.71M |
|
49
Edwards Lifesciences
EW
$47.8B
| $2.4M | 0.73% | +30,000 | New | +$2.4M |
|
|
HZNP
50
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.33M | 0.71% | 30,000 -50,000 | -63% | -$3.88M |
|